

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

Phospho-PLCgamma2 (Tyr759) Antibody

RRID:AB_2163714

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3874, RRID:AB_2163714

Antibody Information

URL: http://antibodyregistry.org/AB_2163714

Proper Citation: Cell Signaling Technology Cat# 3874, RRID:AB_2163714

Target Antigen: Phospho-PLCgamma2 (Tyr759)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10078316, AB_10078670, AB_2163714.

Antibody Name: Phospho-PLCgamma2 (Tyr759) Antibody

Description: This polyclonal targets Phospho-PLCgamma2 (Tyr759)

Target Organism: h, m, mouse, human

Antibody ID: AB_2163714

Vendor: Cell Signaling Technology

Catalog Number: 3874

Record Creation Time: 20250819T211719+0000

Record Last Update: 20250819T222829+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-PLCgamma2 (Tyr759) Antibody.

No alerts have been found for Phospho-PLCgamma2 (Tyr759) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Feng Y, et al. (2025) TBK1 phagosomal recruitment enhances antifungal immunity via positive feedback regulation with SRC. Cell reports, 44(7), 115972.

Cox EM, et al. (2023) AKT activity orchestrates marginal zone B cell development in mice and humans. Cell reports, 42(4), 112378.

Chen T, et al. (2023) The nucleotide receptor STING translocates to the phagosomes to negatively regulate anti-fungal immunity. Immunity, 56(8), 1727.

Li L, et al. (2023) Asebogenin suppresses thrombus formation via inhibition of Syk phosphorylation. British journal of pharmacology, 180(3), 287.

Chong Y, et al. (2020) Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome. International journal of cancer, 146(8), 2243.

Gui F, et al. (2019) A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. British journal of pharmacology, 176(23), 4491.

Ng PK, et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer cell, 33(3), 450.